Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of mercaptopurine in RB1-NUDT15-deficient small cell lung cancer
ChiCTR2300076506Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mercaptopurine in small cell lung cancer (SCLC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Recommended phase 2 dose (RP2D) and Objective response rate (ORR). Planned start Oct 2023; status: not yet recruiting.
02
Drugs
mercaptopurine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300076506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076506.